Phase 2Update

BMB-101

Epilepsy, Developmental and Epileptic Encephalopathy (DEE), Absence Seizures (AS)

DRUGBright Minds Biosciences

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: BMB-101
Development stage: Phase 2
Event type: Update
Indication: Epilepsy, Developmental and Epileptic Encephalopathy (DEE), Absence Seizures (AS)

Research summary

What is being tracked?

This catalyst tracks a Phase 2 update for BMB-101 in Epilepsy, Developmental and Epileptic Encephalopathy (DEE), Absence Seizures (AS). The expected timing is based on the latest available company guidance and may change.

Development notes

BREAKTHROUGH trial. 9/12/24- Initiated Ph2 trial. 12/7/24- Ph1 data presented at AES'24. 11/6/25- Topline data in early January 2026. 01/06/26:- Ph2 BREAKTHROUGH topline positive in Absence and DEE; registrational trial preparations started.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source